List of Excipients in Branded Drug FIORINAL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allergan Inc	FIORINAL	butalbital, aspirin, and caffeine	0023-6146	CELLULOSE, MICROCRYSTALLINE
Allergan Inc	FIORINAL	butalbital, aspirin, and caffeine	0023-6146	D&C YELLOW NO. 10
Allergan Inc	FIORINAL	butalbital, aspirin, and caffeine	0023-6146	FD&C GREEN NO. 3

Excipient Strategy and Commercial Opportunities for FIORINAL

Last updated: February 25, 2026

What is FIORINAL and what role do excipients play?

FIORINAL is a combination medication comprising butalbital, acetaminophen, and caffeine. It is primarily prescribed for tension headaches and migraine relief. Excipients in FIORINAL serve as inactive ingredients that enhance stability, ensure proper drug delivery, and improve manufacturability.

What are the key excipients in FIORINAL formulations?

Based on marketed formulations [1], FIORINAL typically contains:

• Lactose monohydrate (filler)
• Corn starch (disintegrant)
• Magnesium stearate (lubricant)
• Acetaminophen (active)
• Butalbital (active)
• Caffeine (active)

Additional excipients may include coloring agents or preservatives depending on manufacturer specifications.

How are excipient strategies evolving for FIORINAL?

• Use of alternative fillers: Due to lactose intolerance concerns, manufacturers may explore substitutes such as microcrystalline cellulose or mannitol.
• Disintegrant innovation: Superdisintegrants like crospovidone could improve dissolution profiles.
• Lubricant safety: Magnesium stearate's quantity is optimized for manufacturability without affecting bioavailability. Alternatives like stearic acid are investigated for specific formulations.
• Enhancing stability: Incorporation of antioxidants or buffering agents can stabilize susceptible excipients and active components.

What are the commercial implications of excipient choices?

Market differentiation

• Developing lactose-free versions can tap into the lactose intolerance market segment.
• Formulations that improve bioavailability and onset can command premium pricing.
• Novel excipients that enhance stability extend shelf life, reducing logistics costs and waste.

Regulatory considerations

• Changes in excipients require regulatory review [2], potentially delaying product launches.
• Using well-established excipients minimizes approval times and reduces compliance risks.

Cost considerations

• Sourcing cost-effective excipients with consistent supply can lower manufacturing expenses.
• Switching to bulk suppliers with verified quality controls reduces variability.

Intellectual property

• Patents targeting specific excipient combinations or new disintegrants could provide exclusivity.
• Proprietary excipient blends may offer competitive advantages in formulation.

What are the current industry trends influencing excipient strategies?

• Personalized medicine: Custom formulations for specialty populations (e.g., lactose-free, gluten-free) increase excipient diversification.
• Sustainability: Emphasis on environmentally friendly excipients and biodegradable packaging.
• Regulatory harmonization: Global standards push for standardized excipient lists, reducing complexity in international markets.
• Digital tools: Use of predictive modeling to optimize excipient combinations for efficacy and stability.

What are potential new commercial opportunities?

• Developing alternative formulations (e.g., liquids, dispersible tablets) that differ in excipient composition.
• Incorporating multifunctional excipients that combine disintegrant, binder, and stabilizer roles.
• Creating branded excipient blends with consistent quality for licensees.
• Investing in excipient research to enhance bioavailability and reduce side effects.

Summary table of excipient strategies and opportunities

Strategy	Description	Commercial Opportunity
Lactose replacement	Using microcrystalline cellulose or mannitol	Expand into lactose-sensitive demographics
Advanced disintegrants	Implementing crospovidone or superdisintegrants	Improve onset of action; premium formulations
Stabilization additives	Adding antioxidants or buffers	Extend shelf-life; reduce logistics costs
Custom formulations	Developing liquids or dispersible tablets	Access niche markets, pediatric, geriatrics
Proprietary excipient blends	Creating branded excipient packages	Licensing opportunities, strong brand differentiation

Key Takeaways

• Excipients are crucial for FIORINAL’s formulation stability, manufacturability, and market differentiation.
• Market trends prioritize lactose-free options, stability, and bioavailability enhancements.
• Regulatory pathways influence excipient selection, with well-characterized ingredients minimizing approval time.
• Opportunities exist in developing alternative formulations and proprietary excipient blends.
• Cost, regulatory, and intellectual property considerations shape excipient strategies.

FAQs

1. Can excipient modifications impact FIORINAL’s efficacy?
   Yes. Changes to excipients can affect drug release profiles, stability, and absorption, requiring thorough testing and regulatory approval.

2. Are new excipients approved for use in prescription drugs?
   New excipients undergo regulatory review to establish safety and compatibility; use of established excipients expedites approval.

3. What licensing opportunities exist for excipient innovations in FIORINAL?
   Proprietary excipient blends and formulations can be licensed to generic manufacturers or other pharmaceutical companies.

4. How do manufacturing considerations influence excipient choices?
   Suppliers' consistency, excipient quality, and compatibility with production equipment directly impact formulation stability and manufacturing costs.

5. What impact does excipient choice have on worldwide regulatory compliance?
   Selecting excipients with recognized safety profiles reduces hurdles in global approval pathways, especially within the U.S. and EU markets.

---

References

[1] U.S. Food and Drug Administration. (2021). Drug Product Labeling for Fiorinal.
[2] International Conference on Harmonisation. (2022). Q3A-R2: Impurities in pharmaceuticals.